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INTRODUCTION
The care and treatment of spinal cord injury (SCI) patients has significantly evolved
over the last several decades. There has been great interest and promising research
conducted over this period resulting in advancement of our understanding of the
pathophysiology of SCI on both a biochemical and biomolecular level. Concurrently, there has also been rapid clinical advancements in treating spinal fractures
with improvement in the understanding of the biomechanics of injuries, as well as
improvements in spinal fixation techniques and devices. In addition, there have been
great strides made in the collaborative care and treatment efforts of SCI patients
particularly in the fields of radiology, rehabilitation, trauma, and intensive care.
The developments in SCI treatment have led to a decrease in the overall incidence
of traumatic injuries, particularly in the younger populations. This is mainly a result
of preventative measures and education by the various foundations who focus on
the treatment of SCI patients such as CSRS, ASIA, AAOS, CNS, and AANS. In addition,
there has been a greater emphasis in society on limiting catastrophic injuries such as
through the use of: airbag immobilization in motor vehicles, helmets, and the overall
reduction of high-risk activities.
To provide some background information on the pathophysiology of a traumatic SCI,
it is believed that SCI is multifaceted, with the initial force or compression of the cord
resulting in the primary injury. This is then followed by an inflammatory or biochemical
response that results in further injury to the cord over the subsequent days to weeks.
This is referred to as the secondary injury, and it is this stage of injury that has been the
target of intense research. Currently, there exists multiple novel strategies in dealing with
this secondary injury component including surgical techniques, medical management,
pharmacology, and cell-based therapies which will be discussed below.

SURGICAL TECHNIQUES
Over the last century, it is been established that early decompression of the spinal
cord results in improved neurologic outcomes. However, not until the publication of
the STASCIS study (PLoSOne. 2013 Aug 23;8(8):e72659) has clinical data significantly
demonstrated that early decompression does, indeed, improve neurological outcome.
This study, in which Jefferson Health was the highest enrolled center, showed that
surgical decompression and stabilization in less than 24 hours gave the patient the
greatest chance of improving by up to two neurologic grades in the ASIA scale.
Another area of exciting research has been the use of a biocompatible scaffold polymers for acute spinal cord injury, which is also an option for patients at Jefferson
Health. This scaffold is surgically inserted into the spinal cord at the site of injury and
will break down over several weeks. It is postulated that this polymer modulates the
healing environment in acute injury and provides the structural support in both acute
and chronic injury necessary to promote a local environment supportive of cell survival
and growth within the spinal cord. The INSPIRE trial, a study from InVivo therapeutics
(http://www.invivotherapeutics.com) examined the potential benefit of this NeuroSpinal Scaffold (TM) for safety and neurologic recovery in patients with complete
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Figure 1.
Sagittal T2-weighted MRI demonstrating
post spinal cord injury with increased
signal and edema within the cervical
cord (arrow) along with superimposed
cervical stenosis
thoracic (T2-T12) spinal cord injury. This
study is currently being analyzed and
there appears to be a neurologic benefit
with use of this polymer scaffold. Larger
and more comprehensive studies will
likely take place following final analysis
of the data from this trial.

MEDICAL MANAGEMENT
The medical intensive care treatment of
the patients after their traumatic SCI is also
extremely important in overall recovery
and prognosis. It has been determined
throughout the last several decades that
increased blood flow to the spinal cord
by maintaining patients with an elevated
mean arterial pressure significantly
improves neurologic recovery. This is
akin to elevating the blood pressure in an
acute stroke patient so as to perfuse the
brain penumbra that has not yet reached

JHN JOURNAL

1

9

JHN Journal, Vol. 14 [2019], Iss. 1, Art. 2

Figure 3.
(Left) Sagittal T2-weighted MRI and (Right) CT scan demonstrating a thoracic flexiondistraction injury (fracture dislocation) causing severe spinal cord compression
Figure 2.
Intraoperative lateral radiograph
demonstrating post-surgical instrumented
posterior cervical fusion hardware
terminal ischemia. In addition, there is
interest in the use of hypothermia to
decrease the metabolic bands of the spinal
cord during the acute phase of injury to
help aid in recovery. Jefferson is currently
involved in this study through a grant from
the Department of Defense.

by blocking the rho activation system. In
the initial phase 1 study, which compared
the medication to case controls, not
only was the medication safe, but it also
showed to be efficacy. Unfortunately,
when the medication was compared
to placebo there was no significant
improvement, so the trial was ultimately
halted. However, the study did result in
greater interest in the investigation of
drugs to treat and modulate injuries to
the spinal cord.

PHARMACOLOGY
The largest international SCI pharmacological multicentered prospective
randomized controlled study is presently
being run through the AO Foundation.
Jefferson is currently the largest clinical
enrolling site in North America. This study
is investigating the drug, Riluzole, which
is approved for patients with ALS, and its
effect on reducing excitatory apoptosis
(cell-initiated death) after an injury to the
spinal cord. This is a continuation of a
phase 1 study, also done at Jefferson,
which showed safety of the medication.
Unfortunately, not all promising initial
studies are confirmed during their phase
3 trials. Recently, Jefferson was involved
with the Vertex SCI trial which examined
a medication to prevent cell apoptosis
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CELL-BASED THERAPIES
There is a good deal of excitement about
the possibility of cell mediated interventions being used to improve neurologic
outcomes after SCI. We are very fortunate at Jefferson to have been asked to
participate in many studies investigating
this topic and strategy. The first stem cell
spinal cord injury trials were performed
by Geron Corporation, although, they
were eventually halted and sold to
a secondary company that became
known as Asterias (https://asteriasbiotherapeutics.com). Asterias has been a
proponent of intraparenchymal spinal
cord injection of stem cells. Unlike some
other cell-based strategies, these do not
target the neurons directly but rather the

oligodendrocytes, which function to
provide support and myelin production
in the central nervous system.
In another trial, named the StemCell Inc
trial, HuCNS stem cells were implanted
through direct spinal cord parenchymal
injections within one year of the injury.
Despite showing promising improvements
in neurologic recovery, the study was
unfortunately halted due to financial issues.
Currently, there is an active trial investigating the use of Schwann cell transplants
being performed at the University of
Miami. This study uses Schwann cells
harvested from the patient and transfers
them directly into spinal cord injury site.
The results of the phase 1 portion of this
trial were published in 2017 and showed
the safety of this treatment, noting that
there were no adverse events or serious
adverse events related to the cell therapy.
It is important to realize, however, that
that with any new treatment, there can
be significant complications. Particularly
related to cell-based therapies, such as
implantation of stem cells, there is the
possibility for inducing aberrant growth of
non-spinal cord tissue which has potential
to harm the surrounding neural structures.
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CONCLUSION
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